Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03989414 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
A Phase 1 study of Multiple Myeloma, sponsored by Celgene.
- Active
- Registry status
- Phase 1
- Development phase
- 424
- Enrollment target
- 20
- Study locations
NCT03989414: Active Phase 1 study of Multiple Myeloma, sponsored by Celgene.
NCT03989414 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Celgene. The registered enrollment target is 424 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03989414, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Celgene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 424 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG Carfilzomib
- DRUG Bortezomib
- DRUG CC-92480
Study Locations (20)
Massachusetts
- Local Institution - 117 - Boston
- Local Institution - 101 - Boston
- Local Institution - 118 - Boston
Illinois
- Local Institution - 112 - Chicago
- Local Institution - 107 - Chicago
Alberta
- Local Institution - 201 - Calgary
- Local Institution - 205 - Edmonton
Colorado
- Local Institution - 119 - Denver
Florida
- Local Institution - 104 - Tampa
Georgia
- Local Institution - 108 - Atlanta
Michigan
- Local Institution - 113 - Detroit
Minnesota
- Local Institution - 106 - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 1 |
What the registry record for NCT03989414 still lists
NCT03989414 is an interventional study that assigns participants to a tested intervention. The registered 424 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT03989414 names 20 study sites across 16 states, led by Massachusetts, Illinois, Alberta.
Frequently Asked Questions
What is clinical trial NCT03989414 about?
NCT03989414 is a clinical study titled "A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)". The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
What is the current status of trial NCT03989414?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 424 participants. The study started on 2019-09-30. Estimated completion is 2026-11-30.
What conditions does trial NCT03989414 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03989414?
The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Carfilzomib (DRUG), Bortezomib (DRUG), CC-92480 (DRUG).
Who is sponsoring clinical trial NCT03989414?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03989414 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03989414's enrollment target sits among peer trials
424 56th of 438 higher than 383 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05632770 · 424 participants · NA
A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems
- NCT05733767 · 424 participants · Phase 2
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
- NCT06978127 · 424 participants · NA
Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients
- NCT07140913 · 424 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI